Patents by Inventor Cheng-Tsung Lai

Cheng-Tsung Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240150354
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: August 24, 2023
    Publication date: May 9, 2024
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Patent number: 11919908
    Abstract: The present application provides deazaguaine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: March 5, 2024
    Assignee: Incyte Corporation
    Inventors: Andrew W. Buesking, Onur Atasoylu, Cheng-Tsung Lai, Padmaja Polam, Liangxing Wu, Wenqing Yao
  • Patent number: 11780840
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: October 10, 2023
    Assignee: Incyte Corporation
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Patent number: 11767323
    Abstract: The present application provides tricyclic pyridone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: September 26, 2023
    Assignee: Incyte Corporation
    Inventors: Kai Liu, Onur Atasoylu, Yu Bai, Andrew W. Buesking, Leah C. Konkol, Cheng-Tsung Lai, Song Mei, Jun Pan, Liangxing Wu, Wenqing Yao
  • Publication number: 20220213108
    Abstract: The present application provides deazaguaine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: December 20, 2021
    Publication date: July 7, 2022
    Inventors: Andrew W. Buesking, Onur Atasoylu, Cheng-Tsung Lai, Padmaja Polam, Liangxing Wu, Wenqing Yao
  • Publication number: 20220169649
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: July 1, 2021
    Publication date: June 2, 2022
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Publication number: 20220002299
    Abstract: The present application provides tricyclic pyridone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: July 1, 2021
    Publication date: January 6, 2022
    Inventors: Kai Liu, Onur Atasoylu, Yu Bai, Andrew W. Buesking, Leah C. Konkol, Cheng-Tsung Lai, Song Mei, Jun Pan, Liangxing Wu, Wenqing Yao